What Is Prostate Cancer?

Prostate cancer is a malignancy originating in the epithelial cells of the prostate gland, a small exocrine organ in the male urogenital system that produces fluid components of semen. It is the most commonly diagnosed solid-organ cancer in men in many countries and represents a major focus of biomedical engineering research because of the profound role that imaging systems, sensor technologies, and machine learning methods play in its detection, staging, and treatment. Unlike many malignancies, prostate cancer often grows slowly, and a significant proportion of cases are clinically indolent, making the distinction between aggressive and low-risk disease one of the central diagnostic challenges in the field.

Research in prostate cancer spans molecular biology, radiology, radiation physics, and computational methods, with IEEE-affiliated researchers contributing particularly in signal processing, medical image analysis, and biomedical instrumentation. The disease is classified by Gleason grade, a histological scoring system that describes the architectural pattern of tumor cells observed in biopsy tissue, with higher grades indicating more aggressive phenotypes.

Diagnosis and Biomarkers

Prostate-specific antigen (PSA) is a glycoprotein produced by prostate epithelial cells and secreted into blood serum at measurable concentrations. Elevated PSA levels prompt clinical investigation, although PSA lacks the specificity needed to distinguish prostate cancer from benign prostatic hyperplasia or prostatitis, leading to substantial rates of unnecessary biopsy. PSA density, which normalizes the serum PSA value by prostate volume measured on imaging, improves specificity. Research integrating PSA density as a biomarker into deep learning MRI segmentation models has demonstrated that combining the blood-based biomarker with image features produces more accurate lesion size predictions than imaging alone. Ongoing work focuses on liquid biopsy approaches, including circulating tumor DNA and exosome-based markers, as potential supplements or replacements for PSA screening.

Imaging and AI-Assisted Detection

Multiparametric magnetic resonance imaging (mpMRI) has become the standard pre-biopsy assessment tool for clinically significant prostate cancer. The technique combines T2-weighted structural imaging, diffusion-weighted imaging, and dynamic contrast-enhanced sequences into a composite picture that allows radiologists to assign lesion suspicion scores using the Prostate Imaging Reporting and Data System (PI-RADS) framework. MRI-guided fusion biopsy, which overlays a pre-procedure MRI on real-time ultrasound during needle placement, targets suspicious lesions with greater precision than the systematic random sampling biopsy it is displacing. A systematic review of AI tools for MRI-based prostate cancer diagnosis found that deep learning systems achieved area-under-the-curve scores of up to 0.97 on detection tasks and outperformed the majority of general radiologist readers in multi-reader studies, though the authors cautioned that validation in diverse clinical populations is required before deployment at scale. Deep convolutional neural networks applied to prostate MRI have been studied for fully automated detection and Gleason grade prediction, reducing reader variability and providing consistent second-opinion assessment.

Treatment Approaches

Treatment selection depends on disease stage and grade, patient age, and comorbidities. Localized low-risk prostate cancer is often managed with active surveillance, deferring treatment until clinical progression is evident. Curative-intent options include radical prostatectomy and radiation therapy in the forms of external beam radiotherapy and brachytherapy, in which radioactive seeds are implanted directly into the gland. Advanced cases are treated with androgen deprivation therapy, as prostate cancer cells rely on testosterone for proliferation, and with chemotherapy, targeted agents, or radioligand therapies for metastatic disease. Engineering contributions in this domain include robotic surgical systems, intensity-modulated radiation treatment planning, and real-time intraoperative imaging.

Applications

Prostate cancer research and clinical management intersect with engineering and technology in several domains, including:

• Medical imaging systems design and signal processing for MRI and ultrasound
• Machine learning models for computer-aided detection and Gleason grading
• Robotic-assisted surgical platforms for laparoscopic prostatectomy
• Radiation treatment planning and dosimetry systems
• Implantable biosensors and point-of-care diagnostic devices for biomarker monitoring